Kernal Biologics

Kernal Biologics

Cambridge, MA-based company developing targeted mRNA therapeutics for cancer and other diseases.

Kernal Biologics; a Cambridge, Massachusetts-based company, was founded by Yusuf Erkul, Burak Yilmaz, and Cafer Ozdemir in 2016.

Kernal is a synthetic biology company developing onco-selective messenger RNA (mRNA) for cancer immunotherapies. Additionally, Kernal utilizes deep learning methods to further research and drug development. By employing codon-engineering in therapeutic development, Kernal is looking to empower specific cells, within the human body, to create their own treatments and medicine as a cancer treatment.

In 2019, Kernal Biologics was accepted into the Spring MassBio's MassCONNECT, a two month mentorship program where industry experts educate and lead entrepreneurs to better develop their business plan, launch, and raising capital. This process allows leading experts to identify strengths, weaknesses, opportunities, and threats to the young companies.

COVID-19 Response:

Kernal Biologics began creating immunotherapy for COVID-19 after the mass outbreak in early 2020 by leveraging deep learning and synthetic biology.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Kernal Biologics Seed round, August 2020
125,000
August 25, 2020
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.